利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

9 条记录 (耗时 0.029 秒)

    USE OF GLP-1 AND AGONISTS THEREOF TO PREVENT CARDIAC MYOCYTE APOPTOSIS
    1.
    发明申请
    USE OF GLP-1 AND AGONISTS THEREOF TO PREVENT CARDIAC MYOCYTE APOPTOSIS 审中-公开
    使用GLP-1及其预防心脑血管疾病的药物

    公开(公告)号：US20090264352A1

    公开(公告)日：2009-10-22

    申请号：US11857951

    申请日：2009-06-17

    申请人： Christen ANDERSON ,  Alain D. Baron

    发明人： Christen ANDERSON ,  Alain D. Baron

    IPC分类号： A61K38/22 ,  A61P9/00

    CPC分类号： A61K38/26

    摘要： The present invention relates generally to the novel use of GLP-1, including analogs, and agonists, to prevent cardiac myocyte apoptosis. The present invention relates to methods for using GLP-1 for the treatment of conditions associated with cardiac myocyte apoptosis. The present invention further relates to improving the efficiency of cardiac myocytes and also to improving cardiac contractility.

    摘要翻译： 本发明一般涉及GLP-1（包括类似物和激动剂）用于预防心肌细胞凋亡的新用途。 本发明涉及使用GLP-1用于治疗与心肌细胞凋亡相关的病症的方法。 本发明还涉及提高心肌细胞的效率和改善心肌收缩力。

    Use of exendin and analogs thereof to delay or prevent cardiac remodeling
    3.
    发明授权
    Use of exendin and analogs thereof to delay or prevent cardiac remodeling 有权
    毒蜥外泌肽及其类似物的使用可延缓或预防心脏重塑

    公开(公告)号：US08946149B2

    公开(公告)日：2015-02-03

    申请号：US11910730

    申请日：2006-04-11

    申请人： Christen Anderson ,  Que Liu

    发明人： Christen Anderson ,  Que Liu

    IPC分类号： A61K38/26 ,  A61P9/10 ,  A61K38/22 ,  C07K14/605

    CPC分类号： A61K38/26 ,  A61K38/2278

    摘要： The present invention relates generally to the novel use of cardioprotective incretin compounds (CICs) such as GLP-1 and exendin and agonists thereof, including analogs and derivatives to prevent, delay, attenuate, or ameliorate cardiac remodeling. The present invention relates to methods for using CICs for the treatment of conditions associated with cardiac remodeling. The present invention further relates to methods for using CICs for the reduction of the risk or severity of congestive heart failure.

    摘要翻译： 本发明一般涉及心脏保护性肠降血糖素化合物（CIC）如GLP-1和毒蜥外泌肽及其激动剂的新用途，包括类似物和衍生物以预防，延缓，减弱或改善心脏重塑。 本发明涉及使用CIC来治疗与心脏重塑有关的病症的方法。 本发明还涉及使用CIC降低充血性心力衰竭的风险或严重程度的方法。

    Use of GLP-1, Exendin and Agonists Thereof To Delay or Prevent Cardiac Remodeling
    4.
    发明申请
    Use of GLP-1, Exendin and Agonists Thereof To Delay or Prevent Cardiac Remodeling 有权
    使用GLP-1，毒蜥外泌肽和激动剂来延缓或预防心脏重塑

    公开(公告)号：US20090137466A1

    公开(公告)日：2009-05-28

    申请号：US11910730

    申请日：2006-04-11

    申请人： Christen Anderson ,  Que Liu

    发明人： Christen Anderson ,  Que Liu

    IPC分类号： A61K38/22 ,  A61P7/00

    CPC分类号： A61K38/26 ,  A61K38/2278

    摘要： The present invention relates generally to the novel use of cardioprotective incretin compounds (CICs) such as GLP-1 and exendin and agonists thereof, including analogs and derivatives to prevent, delay, attenuate, or ameliorate cardiac remodeling. The present invention relates to methods for using CICs for the treatment of conditions associated with cardiac remodeling. The present invention further relates to methods for using CICs for the reduction of the risk or severity of congestive heart failure.

    摘要翻译： 本发明一般涉及心脏保护性肠降血糖素化合物（CIC）如GLP-1和毒蜥外泌肽及其激动剂的新用途，包括类似物和衍生物以预防，延缓，减弱或改善心脏重塑。 本发明涉及使用CIC来治疗与心脏重塑有关的病症的方法。 本发明还涉及使用CIC降低充血性心力衰竭的风险或严重程度的方法。

    Use of GLP-1 and agonists thereof to prevent cardiac myocyte apoptosis
    7.
    发明申请
    Use of GLP-1 and agonists thereof to prevent cardiac myocyte apoptosis 审中-公开
    使用GLP-1及其激动剂来预防心肌细胞凋亡

    公开(公告)号：US20070021336A1

    公开(公告)日：2007-01-25

    申请号：US11313763

    申请日：2005-12-22

    申请人： Christen Anderson ,  Alain Baron

    发明人： Christen Anderson ,  Alain Baron

    IPC分类号： A61K38/26

    CPC分类号： A61K38/26

    摘要： The present invention relates generally to the novel use of GLP-1, including analogs, and agonists, to prevent cardiac myocyte apoptosis. The present invention relates to methods for using GLP-1 for the treatment of conditions associated with cardiac myocyte apoptosis. The present invention further relates to improving the efficiency of cardiac myocytes and also to improving cardiac contractility.

    摘要翻译： 本发明一般涉及GLP-1（包括类似物和激动剂）在预防心肌细胞凋亡中的新用途。 本发明涉及使用GLP-1用于治疗与心肌细胞凋亡相关的病症的方法。 本发明还涉及提高心肌细胞的效率和改善心肌收缩力。